Clinical Trials · NCT01786915
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 30
- Start date
- Feb 2013
- Locations
- 1 site, United States
- Primary endpoint
- Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 1 in each cohort.